Advanzeon Solutions
OTCMKTS:CHCRAdvanzeon Solutions, Inc., through its subsidiary, Pharmacy Value Management Solutions, Inc., administers and operates a sleep apnea program known as SleepMaster Solutions. The company was formerly known as Comprehensive Care Corporation and changed its name to Advanzeon Solutions, Inc. in January 2014. Advanzeon Solutions, Inc. was founded in 1969 and is headquartered in Tampa, Florida. On September 8, 2022, the voluntary petition of Advanzeon Solutions, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 7, 2020.
Capital Senior Living
NYSE:CSUCapital Senior Living Corp. engages in the operation of senior housing communities. Its senior living options include independent living, assisted living, and memory care. The company was founded in 1990 and is headquartered in Dallas, TX.
HTG Molecular Diagnostics
NASDAQ:HTGMHTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Neurotrope
NASDAQ:NTRPNeurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.